Emmaus Life Sciences, Inc. (EMMA)
USD 0.02
(-12.28%)
USD 0.02
(-12.28%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 28.25 Million USD | 78.6% |
| 2022 | 15.8 Million USD | -8.65% |
| 2021 | 17.29 Million USD | -17.31% |
| 2020 | 20.91 Million USD | -3.41% |
| 2019 | 21.65 Million USD | 4337.21% |
| 2018 | 488.1 Thousand USD | 550.8% |
| 2017 | 75 Thousand USD | -5.78% |
| 2016 | 79.6 Thousand USD | -16.39% |
| 2015 | 95.2 Thousand USD | 53.3% |
| 2014 | 62.1 Thousand USD | 630.77% |
| 2013 | -11.7 Thousand USD | 31.18% |
| 2012 | -17 Thousand USD | -102.84% |
| 2011 | 598.8 Thousand USD | 18.95% |
| 2010 | 503.4 Thousand USD | -11.45% |
| 2009 | 568.5 Thousand USD | -6.85% |
| 2008 | 610.3 Thousand USD | 745.29% |
| 2007 | 72.2 Thousand USD | 0.0% |
| 2006 | - USD | 0.0% |
| 2005 | - USD | 0.0% |
| 2004 | - USD | -100.0% |
| 2003 | 5911.00 USD | -11.55% |
| 2002 | 6683.00 USD | -6.28% |
| 2001 | 7131.00 USD | -15.92% |
| 2000 | 8481.00 USD | -15.19% |
| 1999 | 10 Thousand USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 2.24 Million USD | -67.29% |
| 2024 Q2 | 5.13 Million USD | 128.37% |
| 2023 Q4 | 6.87 Million USD | 43.13% |
| 2023 Q2 | 10.25 Million USD | 62.1% |
| 2023 Q1 | 6.32 Million USD | 19.66% |
| 2023 FY | 28.22 Million USD | 78.6% |
| 2023 Q3 | 4.8 Million USD | -53.14% |
| 2022 Q3 | 4.39 Million USD | 13.06% |
| 2022 Q4 | 5.28 Million USD | 20.14% |
| 2022 FY | 15.8 Million USD | -8.65% |
| 2022 Q1 | 2.22 Million USD | 118.55% |
| 2022 Q2 | 3.89 Million USD | 74.72% |
| 2021 Q3 | 5.32 Million USD | -12.18% |
| 2021 Q2 | 6.05 Million USD | 23.68% |
| 2021 Q1 | 4.89 Million USD | -9.48% |
| 2021 FY | 17.29 Million USD | -17.31% |
| 2021 Q4 | 1.01 Million USD | -80.85% |
| 2020 Q2 | 3.91 Million USD | -39.56% |
| 2020 Q1 | 6.47 Million USD | 30.28% |
| 2020 Q3 | 5.11 Million USD | 30.74% |
| 2020 Q4 | 5.41 Million USD | 5.77% |
| 2020 FY | 20.91 Million USD | -3.41% |
| 2019 FY | 21.65 Million USD | 4337.21% |
| 2019 Q2 | 119.4 Thousand USD | -27.11% |
| 2019 Q3 | 5.9 Million USD | 4846.4% |
| 2019 Q1 | 163.8 Thousand USD | 1.11% |
| 2019 Q4 | 4.97 Million USD | -15.83% |
| 2018 Q4 | 162 Thousand USD | 14.16% |
| 2018 Q2 | 147.5 Thousand USD | -8.73% |
| 2018 Q1 | 161.6 Thousand USD | 335.58% |
| 2018 Q3 | 141.9 Thousand USD | -3.8% |
| 2018 FY | 488.1 Thousand USD | 550.8% |
| 2017 Q3 | 4200.00 USD | -82.64% |
| 2017 Q1 | 28.1 Thousand USD | 51.89% |
| 2017 Q2 | 24.2 Thousand USD | -13.88% |
| 2017 Q4 | 37.1 Thousand USD | 783.33% |
| 2017 FY | 75 Thousand USD | -5.78% |
| 2016 Q1 | 19.3 Thousand USD | -17.87% |
| 2016 Q4 | 18.5 Thousand USD | 7.56% |
| 2016 Q3 | 17.2 Thousand USD | -12.24% |
| 2016 FY | 79.6 Thousand USD | -16.39% |
| 2016 Q2 | 19.6 Thousand USD | 1.55% |
| 2015 Q3 | 24.7 Thousand USD | -17.11% |
| 2015 Q1 | 19.1 Thousand USD | -11.57% |
| 2015 FY | 95.2 Thousand USD | 53.3% |
| 2015 Q4 | 23.5 Thousand USD | -4.86% |
| 2015 Q2 | 29.8 Thousand USD | 56.02% |
| 2014 FY | 62.1 Thousand USD | 630.77% |
| 2014 Q3 | 23.8 Thousand USD | 13.88% |
| 2014 Q4 | 21.6 Thousand USD | -9.24% |
| 2014 Q1 | 9900.00 USD | 33.78% |
| 2014 Q2 | 20.9 Thousand USD | 111.11% |
| 2013 Q1 | -6400.00 USD | -100.0% |
| 2013 FY | -11.7 Thousand USD | 31.18% |
| 2013 Q3 | 10.8 Thousand USD | 183.72% |
| 2013 Q4 | 7400.00 USD | -31.48% |
| 2013 Q2 | -12.9 Thousand USD | -101.56% |
| 2012 Q4 | -3200.00 USD | 99.35% |
| 2012 Q2 | 155.3 Thousand USD | -12.85% |
| 2012 FY | -17 Thousand USD | -102.84% |
| 2012 Q1 | 178.2 Thousand USD | 22.81% |
| 2012 Q3 | -495.4 Thousand USD | -419.0% |
| 2011 Q2 | 160 Thousand USD | 3.03% |
| 2011 FY | 598.8 Thousand USD | 18.95% |
| 2011 Q4 | 145.1 Thousand USD | -15.49% |
| 2011 Q1 | 155.3 Thousand USD | 38.91% |
| 2011 Q3 | 171.7 Thousand USD | 7.31% |
| 2010 Q2 | 126.4 Thousand USD | -9.0% |
| 2010 Q1 | 138.9 Thousand USD | 21.95% |
| 2010 FY | 503.4 Thousand USD | -11.45% |
| 2010 Q3 | 124.3 Thousand USD | -1.66% |
| 2010 Q4 | 111.8 Thousand USD | -10.06% |
| 2009 Q3 | 140.1 Thousand USD | 8.02% |
| 2009 Q4 | 113.9 Thousand USD | -18.7% |
| 2009 FY | 568.5 Thousand USD | -6.85% |
| 2009 Q1 | 148.2 Thousand USD | 7.31% |
| 2009 Q2 | 129.7 Thousand USD | -12.48% |
| 2008 Q2 | 198.7 Thousand USD | 26.64% |
| 2008 Q1 | 156.9 Thousand USD | 654.33% |
| 2008 Q4 | 138.1 Thousand USD | -40.96% |
| 2008 FY | 610.3 Thousand USD | 745.29% |
| 2008 Q3 | 233.9 Thousand USD | 17.72% |
| 2007 FY | 72.2 Thousand USD | 0.0% |
| 2007 Q4 | 20.8 Thousand USD | 0.0% |
| 2007 Q3 | - USD | -100.0% |
| 2007 Q1 | 36.1 Thousand USD | 0.0% |
| 2007 Q2 | 31.6 Thousand USD | -12.47% |
| 2006 Q4 | - USD | -100.0% |
| 2006 Q3 | 31.6 Thousand USD | 384.68% |
| 2006 Q2 | -11.1 Thousand USD | 0.0% |
| 2006 Q1 | - USD | 0.0% |
| 2006 FY | - USD | 0.0% |
| 2005 Q2 | - USD | 0.0% |
| 2005 FY | - USD | 0.0% |
| 2005 Q4 | - USD | 0.0% |
| 2005 Q3 | - USD | 0.0% |
| 2005 Q1 | - USD | 100.0% |
| 2004 Q4 | -58.28 Thousand USD | 0.0% |
| 2004 FY | - USD | -100.0% |
| 2004 Q1 | - USD | -100.0% |
| 2004 Q3 | - USD | -100.0% |
| 2004 Q2 | 20.73 Thousand USD | 0.0% |
| 2003 FY | 5911.00 USD | -11.55% |
| 2003 Q1 | 1852.00 USD | 80.86% |
| 2003 Q4 | 1610.00 USD | 74.81% |
| 2003 Q3 | 921.00 USD | -39.76% |
| 2003 Q2 | 1529.00 USD | -17.44% |
| 2002 Q1 | 2614.00 USD | -5.6% |
| 2002 FY | 6683.00 USD | -6.28% |
| 2002 Q4 | 1024.00 USD | -27.94% |
| 2002 Q3 | 1421.00 USD | -12.45% |
| 2002 Q2 | 1623.00 USD | -37.91% |
| 2001 Q2 | 1857.00 USD | 4.27% |
| 2001 FY | 7131.00 USD | -15.92% |
| 2001 Q1 | 1781.00 USD | 0.0% |
| 2001 Q4 | 2769.00 USD | 282.46% |
| 2001 Q3 | 724.00 USD | -61.01% |
| 2000 Q4 | - USD | 0.0% |
| 2000 Q2 | - USD | 0.0% |
| 2000 FY | 8481.00 USD | -15.19% |
| 2000 Q1 | - USD | -100.0% |
| 2000 Q3 | - USD | 0.0% |
| 1999 FY | 10 Thousand USD | 0.0% |
| 1999 Q4 | 10 Thousand USD | 0.0% |
| 1999 Q3 | - USD | -100.0% |
| 1999 Q2 | 10 Thousand USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | -2439.00 USD | 1158566.585% |
| Evofem Biosciences, Inc. | 11.7 Million USD | -141.372% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | 8943.312% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | 76.278% |
| Qrons Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | 209.524% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | 58648.664% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | 22840.26% |
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | -88.379% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | -910763.959% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| SQZ Biotechnologies Company | 9.79 Million USD | -188.493% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | -42887.768% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | 82837.921% |
| Mesoblast Limited | -35.16 Million USD | 180.343% |
| Marizyme, Inc. | 457.7 Thousand USD | -6073.231% |
| Genus plc | 178.7 Million USD | 84.189% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| Pharming Group N.V. | 220.1 Million USD | 87.163% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | -45307.065% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | -6788.691% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | 256963.636% |
| ContraFect Corporation | -154 Thousand USD | 18447.403% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | 56610.0% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | -36709.057% |
| IMV Inc. | -962.29 Thousand USD | 3036.201% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | 7391.594% |
| MultiCell Technologies, Inc. | 49.32 USD | -57289032.198% |
| ONE Bio Corp. | 20.12 Million USD | -40.394% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 40.26 Million USD | 29.827% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 48.9 Thousand USD | -57681.186% |
| Q BioMed Inc. | -8988.00 USD | 314463.596% |
| Mosaic ImmunoEngineering Inc. | - USD | -Infinity% |
| Biomind Labs Inc. | -15.42 Thousand USD | 183288.537% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | 36.302% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | 2575.096% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | -40264.286% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | -4952.00 USD | 570677.544% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | -20010.32% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | 29075.029% |
| GB Sciences, Inc. | -624.00 USD | 4528144.872% |
| Alpha Cognition Inc. | -86.02 Thousand USD | 32943.958% |
| HST Global, Inc. | - USD | -Infinity% |
| CSL Limited | 7.56 Billion USD | 99.626% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Halberd Corporation | -208.00 USD | 13584234.615% |
| Enzolytics Inc. | 30.7 Thousand USD | -91911.854% |
| Agentix Corp. | - USD | -Infinity% |
| Resverlogix Corp. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | -5756.772% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.1 Billion USD | 97.451% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | 5591.633% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | -4476.568% |
| Zenith Capital Corp. | - USD | -Infinity% |
| Genscript Biotech Corporation | 409.55 Million USD | 93.101% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | 319149.232% |
| WPD Pharmaceuticals Inc. | - USD | -Infinity% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | 33797.48% |
| Kadimastem Ltd | -630.13 Thousand USD | 4583.938% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | -2759.873% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 9.61 Million USD | -193.986% |
| BioStem Technologies, Inc. | 15.42 Million USD | -83.178% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | - USD | -Infinity% |
| LadRx Corporation | -11.83 Thousand USD | 238841.022% |
| Cell Source, Inc. | - USD | -Infinity% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -15903.058% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -15903.058% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Affymax, Inc. | 1.35 Million USD | -1981.947% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| CytoDyn Inc. | -29 Thousand USD | 97531.034% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | -6178.289% |
| SYBLEU INC | 11.69 Thousand USD | -241478.317% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | -Infinity% |
| International Stem Cell Corporation | 4.6 Million USD | -513.173% |
| Bioxytran, Inc. | -8285.00 USD | 341138.021% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | - USD | -Infinity% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | 7675.067% |
| Neutra Corp. | 14.33 Thousand USD | -197004.988% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | 34557.317% |
| PureTech Health plc | -1.6 Million USD | 1862.633% |
| Coeptis Therapeutics, Inc. | -1 Million USD | 2922.012% |
| IXICO plc | 3.27 Million USD | -764.067% |
| IntelGenx Technologies Corp. | -694 Thousand USD | 4171.326% |
| Gelesis Holdings, Inc. | -1.79 Million USD | 1677.61% |
| CSL Limited | 7.7 Billion USD | 99.633% |
| Cellectis S.A. | 18 Thousand USD | -156872.222% |